Vulvovaginal Atrophy (VVA), caused by low estrogen levels, can severely impinge on quality-of-life in post-menopausal women and breast cancer patients.  As many as 50% of post-menopausal women experience significant symptoms that include vaginal dryness, burning and itching, and discomfort during intercourse. Izun’s IZN-6N-AV is a unique, non-hormonal solution to resolve these symptoms and to treat dyspareunia (pain on intercourse) due to low hormonal levels.

A recent proof-of-concept Phase IIa trial was successfully completed. The data demonstrated a highly significant reduction in VVA and associated symptoms. Preparations for a Phase II trial are in process.

Izun’s IZN-6N-AV, the estrogen-free solution to this intimate issue, will become the product of choice in this market.

Market size is estimated at $1.9B.